Filing Details
- Accession Number:
- 0001493152-21-015911
- Form Type:
- 4/A
- Zero Holdings:
- No
- Publication Time:
- 2021-07-01 21:56:31
- Reporting Period:
- 2021-03-30
- Accepted Time:
- 2021-07-01 21:56:31
- Original Submission Date:
- 2021-04-01
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1349929 | Vyant Bio Inc. | VYNT | Services-Medical Laboratories (8071) | 043462475 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1850698 | Marcus Boehm | C/O Vyant Bio, Inc. 2370 State Route 70, Suite 310 Cherry Hill, NJ 08002 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 Par Value | Acquisiton | 2021-03-30 | 93,786 | $0.00 | 93,786 | No | 4 | J | Direct | |
| Common Stock, $0.0001 Par Value | Disposition | 2021-05-05 | 78,263 | $0.00 | 15,253 | No | 5 | G | Direct | |
| Common Stock, $0.0001 Par Value | Acquisiton | 2021-05-05 | 78,263 | $0.00 | 78,263 | No | 5 | G | Indirect | By Trust |
| Common Stock, $0.0001 Par Value | Disposition | 2021-05-10 | 15,523 | $0.00 | 0 | No | 5 | G | Direct | |
| Common Stock, $0.0001 Par Value | Acquisiton | 2021-05-10 | 15,523 | $0.00 | 93,786 | No | 5 | G | Indirect | By Trust |
| Common Stock, $0.0001 Par Value | Acquisiton | 2021-05-28 | 5,000 | $3.68 | 98,786 | No | 4 | P | Indirect | By Trust |
| Common Stock, $0.0001 Par Value | Acquisiton | 2021-06-30 | 5,000 | $3.76 | 103,786 | No | 4 | P | Indirect | By Trust |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | J | Direct | |
| No | 5 | G | Direct | |
| No | 5 | G | Indirect | By Trust |
| No | 5 | G | Direct | |
| No | 5 | G | Indirect | By Trust |
| No | 4 | P | Indirect | By Trust |
| No | 4 | P | Indirect | By Trust |
Footnotes
- Pursuant to that certain Agreement and Plan of Merger, dated as of August 21, 2020, as amended, by and among Cancer Genetics, Inc. now known as Vyant Bio, Inc. ("Issuer"), CGI Acquisition, Inc., a Minnesota corporation and a wholly-owned subsidiary of Issuer ("Merger Sub") and StemoniX, Inc., a Minnesota corporation ("StemoniX") (the "Merger Agreement"), Reporting Person received shares of the Issuer's common stock, $0.0001 par value (the "Common Stock") in exchange shares of StemoniX common stock, $0.0001 owned prior to the merger.
- The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person under the Boehm Family Trust, Marcus & Kimberley Boehm Trustees on May 24, 2021.
- Shares were previously reported as being directly held by reporting person.
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.70 to $3.8099 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
Billionaire Hedge Funds
